Spyre Therapeutics, Inc.
SYRE
Classifica tra le azioni
#2339
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Prezzo delle azioni
$93.87
Capitalizzazione di mercato
$8.66B
Variazione (1 giorno)
2.70%
Variazione (1 anno)
303.74%
Paese
US
Scambia Spyre Therapeutics, Inc. (SYRE)
Categoria
Healthcare
Ricavi di Spyre Therapeutics, Inc. (SYRE)
Ricavi nel Jun 2026 TTM: $90.49M
Secondo gli ultimi rapporti finanziari di Spyre Therapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $90.49M. Nel 2023, l'azienda ha registrato ricavi di $886.00K una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $2.33M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Spyre Therapeutics, Inc. da 2014 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $90.49M | 0.00% |
| 2024 | 0.00 | -100.00% |
| 2023 | $886.00K | -61.96% |
| 2022 | $2.33M | -87.57% |
| 2021 | $18.74M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | -100.00% |
| 2018 | $3.89M | -25.30% |
| 2017 | $5.21M | 12.47% |
| 2016 | $4.63M | -23.94% |
| 2015 | $6.09M | 0.00% |
| 2014 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 13,850.43% |
US
|
|
| $2.23B | 2,362.04% |
US
|
|
| $15.74B | 17,298.20% |
AU
|
|
| $6.02B | 6,553.80% |
NL
|
|
| - | - |
CH
|
